Research on the effect of recombinant human growth hormone on the growth and development, muscle volume and bone density of DMD patients with short stature

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078104

Enrollment

Unknown

Registered

2023-11-28

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne muscular dystrophy

Interventions

Growth hormone therapy group:Growth hormone therapy

Observation and treatment group:No growth hormone

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: For patients diagnosed with DMD, the height reaches the short stature standard, the growth rate is slowed down (<5cm/year), and the skeletal muscle volume of the whole body is lower than normal. They were divided into two groups, one was the growth hormone treatment group and the other was the observation and treatment group. ?

Exclusion criteria

Exclusion criteria: Active malignant disease, acute stage of severe systemic infection, patients with symptoms of tumor progression, high risk factors for tumors (radiotherapy, chemotherapy, history of immunosuppressive therapy), hepatitis B virus infection, diabetes

Design outcomes

Primary

Measure	Time frame
Height;Muscle volume;Bone density;	—

Secondary

Measure	Time frame
Weight;Motor function ;Level of vitamin D ;Fasting blood glucose;Fasting insulin;Thyroid function;Body composition analysis;IGF-1/IGFbp3;	—

Countries

China

Contacts

Public ContactXiaotang Cai

West China Second Hospital of Sichuan University

cxt_1999@126.com+86 181 8060 9237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026